138 related articles for article (PubMed ID: 2000644)
1. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
Brøsen K
Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
[TBL] [Abstract][Full Text] [Related]
2. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
[TBL] [Abstract][Full Text] [Related]
4. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
5. [Role of pharmacogenetics in psychopharmacotherapy].
Gram LF
Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
[TBL] [Abstract][Full Text] [Related]
6. The relationship between imipramine metabolism and the sparteine oxidation polymorphism.
Brøsen K
Dan Med Bull; 1988 Oct; 35(5):460-8. PubMed ID: 3066590
[No Abstract] [Full Text] [Related]
7. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
[TBL] [Abstract][Full Text] [Related]
9. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
10. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
12. [Knowledge about metabolic capacity is important in drug therapy].
Alván G; Dahl ML
Lakartidningen; 1992 Feb; 89(6):382, 387-90. PubMed ID: 1738265
[TBL] [Abstract][Full Text] [Related]
13. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
Skjelbo E; Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
[TBL] [Abstract][Full Text] [Related]
14. [Clinical aspects of the polymorphism of oxidation phenotype].
Mrozikiewicz PM
Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):608-10. PubMed ID: 1488339
[No Abstract] [Full Text] [Related]
15. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
17. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Brøsen K; Zeugin T; Meyer UA
Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
[TBL] [Abstract][Full Text] [Related]
18. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
19. [Severe nortriptyline poisoning in poor metabolizers of the sparteine type].
Petersen P; Brøsen K
Ugeskr Laeger; 1991 Feb; 153(6):443-4. PubMed ID: 2000655
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenetics of oxidation reactions of drugs].
Jacqz-Aigrain E
Arch Fr Pediatr; 1989 Jan; 46(1):59-65. PubMed ID: 2653266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
